Dimdazenil
Dimdazenil, sold under the brand name Junoenil, is a medication used in the treatment of insomnia in China.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
Dimdazenil, sold under the brand name Junoenil, is a medication used in the treatment of insomnia in China. It is a benzodiazepine derivative and a partial positive allosteric modulator of the GABA A receptor with two- to four-fold higher functional affinity for the α 1 subunit relative to the α 2 , α 3 , and α 5 subunits.
Medical use
Dimdazenil shows effectiveness in the treatment of insomnia, but has less intrinsic activity in comparison to currently-marketed benzodiazepines and the Z-drugs; however, it is thought that the lower efficacy may result in fewer side effects, such as motor incoordination. In China, dimdazenil is approved for short-term treatment of insomnia.
History
Dimdazenil was originally developed by Roche, based on preclinical data, as a non-sedating anxiolytic, but was found to produce sedation in humans in phase I clinical trials. For this reason, it was subsequently licensed to Evotec, which is now developing it for the treatment of insomnia.
By 2007, dimdazenil completed phase II clinical trials for this indication, with positive findings reported. In China, the drug was developed by Zhejiang Jingxin Pharmaceutical.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1334054027 under CC BY-SA 4.0; modifications have been made.